Ryan Dittamore has developed and commercialized multiple oncology products utilized in medicine today. Most recently, he was CBO of Decipher Biosciences, acquired by Veracyte ($600M), and previously Chief of Medical Innovation at Epic Sciences, where he led the clinical development, reimbursement, guideline support, and commercial partnering of the AR-V7 test (the first predictive test in prostate cancer). Ryan has also held roles at Roche Dx (Ventana), Genisphere (Code Biotherapeutics), and Bio-Rad. Cumulatively, he has partnered with over 60 biopharma companies, is the author of over 30 peer-reviewed publications, and inventor of 12 patents issued and pending.
